Miao-Ping Chien received her PhD in chemistry and biochemistry from the University of California, San Diego in 2013, and went on to do a postdoc at Harvard University, working with Prof. Adam Cohen on technology development for biology (combining biophysics, computation and optical instrumentation).
She joined Erasmus University Medical Center (EMC) as a group leader in June 2017. Her current research focuses on developing and applying multidisciplinary technologies (advanced microscopy and imaging, computation, single cell technology, bioinformatics, (photo)chemistry) to investigate the underlying mechanisms of tumorigenesis, particularly of rare cancer-driving cells. Since becoming a PI, Miao-Ping has received various awards and grants including NWO Veni grant, Oncode Institute junior fellowship, Ammodo Science Award, Cancer GenomiCs.nl (CGC) fellowship, EMC-Delft convergence grant and EMC fellowship. She is a founder of UFO Biosciences, which aims to enable better cancer care by creating treatment options for rare, cancer-driving cell populations that escape traditional treatment.